We were delighted to participate in the Entrepreneurship Series 2026 organised by the Hong Kong Life Sciences Society (HKLSS), where our Principal, Pauli Wong, delivered a session on "Patent Strategy for Life Sciences Spinouts: From Discovery to Deal-Ready IP". Pauli shared practical insights into the various forms of IP and patent protection available to innovators, key considerations for safeguarding life sciences inventions, and the unique IP opportunities and challenges facing businesses operating across the Greater Bay Area (GBA).

Thank you to HKLSS for the invitation and to all attendees for the engaging discussion. Eagle IP remains committed to supporting innovation, entrepreneurship, and the growth of Hong Kong's life sciences ecosystem.

Our Past Events

BioHK2026 | Biotech IP in practice

16 September 2026

Jennifer Che Once Again Named to the IAM Strategy 300

21 August 2026

Yolanda Wang attended the 1st China Pharmaceutical Innovation Conference

22 July 2026

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

16 June 2026

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

5 June 2026

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2 June 2026

Recommended Insights

Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

14 July 2020
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
Read more >

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

6 December 2021
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]
Read more >

When Standards Evolve: How China Judges Inventiveness in Next-Gen Tech Patents

30 September 2025
Starting in 2023, Datang Mobile, one of the key players in China’s telecom standardization efforts, initiated infringement proceedings against Samsung in China, Germany, and the US. Samsung responded by filing multiple invalidation petitions in several jurisdictions, including China, the United States, and Europe. The case discussed below is one of above-mentioned invalidation cases in China, […]
Read more >

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

7 February 2024
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]
Read more >
Top crossarrow-right